Table 1.
Demographic and clinical characteristics of included patients.
| Characteristics | PICU | No PICU | P value |
|---|---|---|---|
| N | 77 | 200 | |
| Number of PICU Encounters | – | ||
| 1 | 51 (66.2%) | – | |
| 2 | 14 (18%) | – | |
| 3 | 12 (16%) | – | |
| Day of Transplant to 1st PICU Event (Days) | – | ||
| Median (IQR) | 51 (310) | – | |
| Age at Transplant (years) | |||
| Median (IQR) | 2.5 (8.8) | 7.1 (10.4) | <0.01 |
| Weight (kg) | |||
| Median (IQR) | 13.3 (20.9) | 22.5 (31.4) | <0.01 |
| BMI (kg/m2) | |||
| N | 76a | 200 | 0.25 |
| Median (IQR) | 17.2 (3.6) | 17.6 (4.6) | |
| BMI Group | |||
| ≤25 | 72 (94.7%) | 182 (91.0%) | 0.31 |
| >25 | 4 (5.3%) | 18 (9.0%) | |
| Race | 0.02 | ||
| Unknown | 5 (6.5%) | 23 (11.5%) | |
| Caucasian | 58 (75.3%) | 154 (77.0%) | |
| African American | 3 (3.9%) | 15 (7.5%) | |
| American Indian | 2 (2.6%) | 3 (1.5%) | |
| Asian | 9 (11.7%) | 5 (2.5%) | |
| Gender | 0.84 | ||
| Male | 44 (57.1%) | 117 (58.5%) | |
| Female | 33 (42.9%) | 83 (41.5%) | |
| Underlying Disease | 0.01 | ||
| Inherited metabolic disorders | 29 (37.7%) | 43 (21.5%) | |
| Non-malignant | 23 (29.9%) | 91 (45.5%) | |
| Malignant | 25 (32.5%) | 66 (33.0%) | |
| Cell source | 0.20 | ||
| Bone marrow | 35 (45.5%) | 110 (55.0%) | |
| PBSC | 3 (3.9%) | 12 (6.0%) | |
| UCB | 39 (50.7%) | 78 (39.0%) | |
| Donor Type (Bone marrow + PBSC) | 0.18 | ||
| Matched sibling | 10 (26.3%) | 49 (40.2%) | |
| Matched URD | 19 (50.0%) | 42 (34.4%) | |
| Mismatched Sibling/URD + Haploidentical | 9 (23.7%) | 31 (25.4%) | |
| CMV matching | 0.04 | ||
| Donor+ Recipient+ | 5 (6.5%) | 38 (19.0%) | |
| Donor+ Recipient- | 8 (10.4%) | 11 (5.5%) | |
| Donor- Recipient+ | 36 (46.8%) | 79 (39.5%) | |
| Donor- Recipient- | 28 (36.8%) | 72 (36.0%) | |
| Conditioning Regimen | 0.01 | ||
| Cyclophosphamide + Fludarabine + TBI | 9 (11.7%) | 50 (25.2%) | |
| Cyclophosphamide + TBI | 14 (18.2%) | 39 (19.7%) | |
| No TBI | 4 (5.2%) | 23 (11.6%) | |
| Busulfan with no TBI | 50 (64.9%) | 86 (43.4%) | |
| LPS/KPS | 0.20 | ||
| ≤80 | 23 (29.9%) | 45 (22.5%) | |
| >80 | 54 (70.1) | 155 (77.5%) | |
| HCT-CI | 0.32 | ||
| 0 | 39 (50.7%) | 121 (60.5%) | |
| 1–2 | 24 (31.7%) | 48 (24.0%) | |
| >=3 | 14 (18.2%) | 31 (15.5%) | |
| DRI | 0.54 | ||
| Very Low | 0 | 5 (2.5%) | |
| Low | 12 (15.6%) | 33 (16.5%) | |
| Intermediate | 12 (15.6%) | 21 (10.5%) | |
| High | 1 (1.3%) | 2 (1.0%) | |
| Very high | 52 (67.5%) | 134 (67.0%) | |
| Missing | 0 | 5 (2.5%) | |
| Cardiopulmonary comorbidity prior to HCT | 0.74 | ||
| Yes | 14 (18.2%) | 33 (16.5%) | |
| No | 63 (81.8%) | 167 (83.5%) | |
| CMV status | 0.86 | ||
| Yes | 20 (26.0%) | 54 (27.0%) | |
| No | 57 (74.0%) | 146 (73.0%) | |
| EBV status | 0.27 | ||
| Yes | 11 (14.3%) | 40 (20.0%) | |
| No | 66 (85.7%) | 160 (80.0%) | |
| Adenovirus status | <0.01 | ||
| Yes | 10 (13.0%) | 7 (3.5%) | |
| No | 67 (87.0%) | 193 (96.5%) | |
| Adenovirus time (days) | |||
| N | 10 | 7 | |
| Median (range) | 77 (71) | 76 (62) | 0.47 |
| Transplant year | 0.33 | ||
| 2015 | 12 (15.6%) | 41 (20.5%) | |
| 2016 | 20 (26.0%) | 32 (16.0%) | |
| 2017 | 13 (16.9%) | 37 (18.5%) | |
| 2018 | 11 (14.3%) | 33 (16.5%) | |
| 2019 | 14 (18.2%) | 28 (14.0%) | |
| 2020 | 7 (9.1) | 29 (14.5%) | |
| ANC engraftment status at last follow-up | 0.50 | ||
| Alive without engrafted | 0 | 1 (0.5%) | |
| Dead without engrafted | 2 (2.6%) | 2 (1.0%) | |
| ANC > 500 × 3 days | 75 (97.4%) | 197 (98.5%) | |
| Follow-up Status | <0.01 | ||
| Alive | 40 (52.0%) | 181 (90.5%) | |
| Dead | 37 (48.0%) | 19 (9.5%) | |
| Alive patients follow up time (days) | <0.01 | ||
| N | 40 | 181 | |
| Median (IQR) | 1,790.5 (737.5) | 1,812 (1,067) | |
| Relapse status at last follow-up | <0.01 | ||
| Alive without relapse | 37 (48.1%) | 173 (86.5%) | |
| Dead without relapse | 32 (41.6%) | 7 (3.5%) | |
| Relapse | 8 (10.4%) | 20 (10.0%) |
BMI, body mass index; UCB, umbilical cord blood; LPS, Lansky Performance Score; KPS, Karnofsky Performance Score; HCT-CI, hematopoietic cell transplant comorbidity index; DRI, disease-risk index; CMV, cytomegalovirus; EBV, Epstein-Barr virus; ANC, absolute neutrophil count.
a
One patient had missing height information and BMI unable to be calculated.